Ciprofibrate
Ciprofibrate structure
|
Common Name | Ciprofibrate | ||
|---|---|---|---|---|
| CAS Number | 52214-84-3 | Molecular Weight | 289.155 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 424.9±45.0 °C at 760 mmHg | |
| Molecular Formula | C13H14Cl2O3 | Melting Point | 114 - 118ºC | |
| MSDS | Chinese USA | Flash Point | 210.7±28.7 °C | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
Transcriptional Regulation of Cytosolic Sulfotransferase 1C2 by Intermediates of the Cholesterol Biosynthetic Pathway in Primary Cultured Rat Hepatocytes.
J. Pharmacol. Exp. Ther. 355 , 429-41, (2015) Cytosolic sulfotransferase 1C2 (SULT1C2) is expressed in the kidney, stomach, and liver of rats; however, the mechanisms regulating expression of this enzyme are not known. We evaluated transcriptional regulation of SULT1C2 by mevalonate (MVA)-derived interme... |
|
|
Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.
Lipids Health Dis. 8 , 50, (2009) CETP is a plasma protein that modulates atherosclerosis risk through its HDL-cholesterol reducing action. The aim of this work was to examine the effect of the PPARalpha agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolip... |
|
|
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Arzneimittelforschung 58(5) , 225-41, (2008) Fibrates are widely prescribed in hyperlpidemic patients to prevent atherosclerosis. Their therapeutic use, however, can be associated with adverse effects like gastrointestinal disorders, myalgia, myositis and hepatotoxicity. In rodents large doses can even ... |
|
|
Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal.
Endocrinology 150(3) , 1192-201, (2009) Seasonal obesity and fasting-associated hibernation are the two major metabolic events governing hepatic lipid metabolism in hibernating mammals. In this process, however, the role of the nuclear receptor known as peroxisome proliferator-activated receptor (P... |
|
|
Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.
Toxicol. Sci. 104(1) , 74-85, (2008) Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands evoke a profound mitogenic response in rodent liver, and the aim of this study was to characterize the kinetics of induction of DNA synthesis. The CAR ligand, 1,4-bis[2-(3,5-dichoropyridylox... |
|
|
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Atherosclerosis 124 Suppl , S21-8, (1996) Triglyceride levels greater than 150 mg/dl are associated with the atherogenic lipoprotein phenotype, represented by a predominance of small, dense low density lipoproteins (LDL) and diminished concentrations of high density lipoproteins. This phenotype is ch... |
|
|
Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
Exp. Cell Res. 317(11) , 1527-33, (2011) Until now, no data are present about the effect of peroxisome proliferator-activated receptor (PPAR)α activation on the prototype Th1 [chemokine (C-X-C motif) ligand (CXCL)10] (CXCL10) and Th2 [chemokine (C-C motif) ligand 2] (CCL2) chemokines secretion in th... |
|
|
PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex.
Biochem. Biophys. Res. Commun. 343(2) , 535-43, (2006) Ciprofibrate, a potent peroxisome proliferator, induces pleiotropic responses in liver by activating peroxisome proliferator-activated receptor alpha (PPARalpha), a nuclear receptor. Transcriptional regulation by liganded nuclear receptors involves the partic... |
|
|
Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes.
Drug Metab. Pharmacokinet. 25(1) , 108-11, (2010) The constitutive androstane receptor (CAR; NR1I3) is a key transcriptional factor that regulates genes encoding drug-metabolizing enzymes and drug transporters. However, studies on regulation of CAR target genes via up- or down-regulation of CAR are limited. ... |
|
|
Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Atherosclerosis 124 Suppl , S83-7, (1996) Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia. In type IIa hypercholesterolaemia, administration of 100 mg... |